Friday, 31 July 2009

Petition - National Health Funding for Low Dose Naltrexone in Australia

http://www.gopetiti on.com/online/ 28354.html

National Health Funding for Low Dose Naltrexone in Australia

Published by Trevor George Stephens
Date: Jun 06, 2009
Category: Health
Region: Australia
Target: Cancer sufferers MS sufferers and HIV+ persons
Web site: http://www.lowdosen altrexone. org

Monday, 27 July 2009

Low Dose Naltrexone (LDN) Dose Timing


UK LDN Now Day - Saturday 12th September 2009

On LDN Now Day, volunteers will be soliciting signatures for the Number 10 LDN Petition -

Read more on the LDN Now Blog here -


And search for #ldnnowday on twitter for more info as it is available.

Wednesday, 22 July 2009

Low Dose Naltrexone (LDN) on The Fourth Plinth, Trafalgar Square, London, Friday July 22nd 2009

This Friday, 22nd of July between 11:00-12:00, Brian Lonsdale will be on the Fourth Plinth in Trafalgar Square, London to focus attention on Low Dose Naltrexone and specifically, the Number 10 petition -

UK Government Petition for Low Dose Naltrexone Trial Funding


Trafalgar Square, Fourth Plinth Web Site

Milford Haven woman petitions government for LDN (Low Dose Naltrexone) trials

Article from The Western Telegraph Newspaper

"Jayne Crocker and her partner Andrew Barnett are both prescribed low dose naltrexone (LDN). They say the generic drug has been used to successfully treat cancer, autoimmune systems and central nervous system disorders. "

http://bit.ly/EVfQm

(MS) Sufferer joins in battle for trials of 'wonder drug' (Low Dose Naltrexone)

Article from This Is South Wales web site -

"
The couple have created a petition to take their fight to 10 Downing Street, and have already gathered around 3,000 signatures.

Mr Barnett, who has secondary progressive MS, said: "We urge the Government to fund a trial of LDN on the NHS."


http://bit.ly/3Iy3sI

Saturday, 4 July 2009

Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot Study

"Results. Low-dose naltrexone reduced fibromyalgia symptoms in the entire cohort, with a greater than 30% reduction of symptoms over placebo. In addition, laboratory visits showed that mechanical and heat pain thresholds were improved by the drug. Side effects (including insomnia and vivid dreams) were rare, and described as minor and transient. Baseline erythrocyte sedimentation rate predicted over 80% of the variance in drug response. Individuals with higher sedimentation rates (indicating general inflammatory processes) had the greatest reduction of symptoms in response to low-dose naltrexone."